HomeCompareCHYMF vs ABBV

CHYMF vs ABBV: Dividend Comparison 2026

CHYMF yields 2.34% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $79.3K in total portfolio value
10 years
CHYMF
CHYMF
● Live price
2.34%
Share price
$0.30
Annual div
$0.01
5Y div CAGR
-0.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.1K
Annual income
$260.58
Full CHYMF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CHYMF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHYMFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHYMF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHYMF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHYMF
Annual income on $10K today (after 15% tax)
$198.76/yr
After 10yr DRIP, annual income (after tax)
$221.49/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,834.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHYMF + ABBV for your $10,000?

CHYMF: 50%ABBV: 50%
100% ABBV50/50100% CHYMF
Portfolio after 10yr
$62.7K
Annual income
$12,516.17/yr
Blended yield
19.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CHYMF
No analyst data
Altman Z
2.0
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHYMF buys
0
ABBV buys
0
No recent congressional trades found for CHYMF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHYMFABBV
Forward yield2.34%3.06%
Annual dividend / share$0.01$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-0.4%40.6%
Portfolio after 10y$23.1K$102.3K
Annual income after 10y$260.58$24,771.77
Total dividends collected$2.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHYMF vs ABBV ($10,000, DRIP)

YearCHYMF PortfolioCHYMF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,933$232.90$11,550$430.00$617.00ABBV
2$11,935$237.02$13,472$627.96$1.5KABBV
3$13,012$240.86$15,906$926.08$2.9KABBV
4$14,167$244.42$19,071$1,382.55$4.9KABBV
5$15,406$247.71$23,302$2,095.81$7.9KABBV
6$16,735$250.76$29,150$3,237.93$12.4KABBV
7$18,160$253.55$37,536$5,121.41$19.4KABBV
8$19,688$256.11$50,079$8,338.38$30.4KABBV
9$21,324$258.45$69,753$14,065.80$48.4KABBV
10$23,078$260.58$102,337$24,771.77$79.3KABBV

CHYMF vs ABBV: Complete Analysis 2026

CHYMFStock

Cahya Mata Sarawak Berhad, an investment holding company, engages in the manufacturing and trading of cement and construction materials, construction, road maintenance, township, and property and infrastructure development businesses in Malaysia. It operates through seven segments: Cement, Construction Materials and Trading, Road Maintenance, Construction, Property Development, Phosphate, and Samalaju Development. The company offers Portland cement; clinker and ready-mix concrete products; pre-cast concrete products, including pre-stressed beams for bridges and other uses, reinforced concrete square piles, box culverts, kerbs, and cement sand bricks; and industrialized building systems, such as wall panels, pre-cast columns and beams, half slabs, hollow blocks, and staircases. It also provides microtonalite, granite, and limestone; delivery, grading, and pavement laying services; steel drawn wires and wire mesh; residential, commercial, and township development, management, and consultancy services; management of temporary accommodation services; supervisory, general trading, software and IT support, education, technical, machinery, and motor vehicle rental services; rehabilitation and maintenance for roads; and construction and road maintenance equipment, as well as supplies premix and road maintenance contractor works. In addition, the company undertakes general construction and infrastructure projects; distributes road and general construction materials, water treatment materials, electrical pipes equipment, and mechanical spare parts; rents investment properties; owns and operates hotels and lodges; and manufactures food, feed, and fertilizer phosphate products. Further, it engages in the mixed-use development and project management activities; and construction of telecommunication towers, as well as undertakes civil engineering, building, and utilities works. The company was founded in 1974 and is headquartered in Kuching, Malaysia.

Full CHYMF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CHYMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHYMF vs SCHDCHYMF vs JEPICHYMF vs OCHYMF vs KOCHYMF vs MAINCHYMF vs JNJCHYMF vs MRKCHYMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.